TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: In-exsufflator Cough Assist Device in Patients With Symptomatic Bronchiectasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chest CT scan confirmation of bronchiectasis~* At least two exacerbations in the preceding 12 months requiring antibiotics~Exclusion Criteria:~* Cystic fibrosis~* Bullous emphysema~* History of spontaneous pneumothorax~* History of massive hemoptysis: greater than 200 cc in a 24 hour period~* Lung resection surgery in the past 6 months~* Use of the mechanical cough in-exsufflator in the prior 3 months~* Inability to speak and read English~* Inability to demonstrate proper use of the cough-assist or flutter device~* Unable to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Assignment to In-Exsufflator Cough Assist Device (Type: ACTIVE_COMPARATOR): In-Exsufflator Cough Assist Device augments the expiratory flow and force of the patient's cough with the addition of a cycle of positive and negative inspiratory pressure when used daily
- Assignment to flutter valve device (Type: ACTIVE_COMPARATOR): flutter valve device delivers expiratory low-pressure vibratory pulse to the patient's airway when used daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Change In Diaphragmatic Thickness Predicts Extubation Success

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* age greater than 18, ventilated for \>24 hours~Exclusion Criteria:~* already chronically on mechanical ventilatory support, already has tracheostomy, has pathology that obscures visualization of the right hemidiaphragm, has acute stroke either hemorrhagic or ischemic, cannot identify appropriate decision maker to get informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Main Cohort (Type: None): all patients enrolled will have an ultrasound of their diaphragm performed once they are on a pressure support trial. Intervention: Diaphragm Ultrasound

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Children With Fever and Respiratory Symptoms at Out-of-hours Services in Norway

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children 0-6 years with fever and/or respiratory symptoms~Exclusion Criteria:~* Children older than 6 years with other conditions

- Gender: ALL
- Minimum Age: None
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- Pre-consultation CRP (Type: ACTIVE_COMPARATOR): Every third child included get a CRP-test before the consultation and the doctor have the answer at start of consultation
- CRP requested (Type: NO_INTERVENTION): No intervention, the consultation with children as normal, the CRP is used at doctors request.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intralipid Therapy for Women 35-40 Years With Positive Natural Killer Cells Undergoing Intracytoplasmic Sperm Injection (ICSI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subfertile women aged 35-40 years with repeated implantation failure or recurrent miscarriage with positive natural killer cells undergoing Intracytoplasmic sperm injection (ICSI ) cycle.~Exclusion Criteria:~* women above 40years or less than 35 years~* Disturbances of normal fat metabolism such as pathologic hyperlipidemia,Lipoid nephrosis or acute pancreatitis with hyperlipidemia.~* Allergic to eggs, soybean oil, or safflower oil.~* Severe liver disease, kidney disease, lung disease, anemia, blood coagulation disorder.~* Uterine fibroid, endometrial polyp, endometriosis and hydrosalpinx.~* Antiphospholipid syndrome (lupus anticoagulant and/or anticardiolipin antibodies (Immunoglobulin G or M)\[IgG or IgM\]); other recognised thrombophilic conditions (testing according to usual clinic practice).~* Intrauterine abnormalities (as assessed by ultrasound, hysterosonography, hysterosalpingogram, or hysteroscopy).~* Fibroids distorting uterine cavity.~* Abnormal parental karyotype.

- Gender: FEMALE
- Minimum Age: 35 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Intralipid infusion (Type: ACTIVE_COMPARATOR): 100 Subfertile women aged 35-40 years with repeated implantation failure or recurrent miscarriage with positive natural killer cells undergoing ICSI cycle.
- Control group (Type: NO_INTERVENTION): 100 Subfertile women aged 35-40 years with repeated implantation failure or recurrent miscarriage with positive natural killer cells undergoing ICSI cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Neotech RAM Cannula Versus Conventional Binasal Prong Continuous Positive Airway Pressure (CPAP) to Treat Respiratory Distress in Low Birth Weight Neonates

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Low Birth Weight Infant~* Currently on continuous positive aireway pressure of 5-7 cm water pressure~* Receiving continuous positive airway pressure support for \> 24 hrs prior to enrollment~* Fraction of inspired oxygen requirement of 23-50%~Exclusion Criteria:~* Fraction of inspired oxygen \> 50%~* Congenital defects of head, pulmonary or cardiovascular systems~* Chromosomal abnormalities/genetic syndromes~* Invasive Surgical Procedure within 24 hrs prior to enrollment~* Enrollment in separate clinical trial that has ongoing data collection

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RAM Cannula CPAP (Type: EXPERIMENTAL): CPAP provided by RAM Cannula
- Binasal Prong CPAP (Type: ACTIVE_COMPARATOR): CPAP provided by binasal prong

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Better Acceptance of Single Injection Apidra Added to Once Daily Lantus Versus Twice Daily Premixed Insulin in Real Life Use Setting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Patients with type 2 diabetes mellitus treated with insulin glargine once daily and oral blood glucose lowering medication~* Patients with a HbA1c \> 7%~* Patients with a FBG within range (4-7 mmol/L) at baseline, based on the mean of 3 FBG values (measured 5x during the run-in phase, with the highest and lowest value excluded)~Exclusion criteria:~* Patients treated with an insulin other than insulin glargine~* Patients with hypersensitivity to insulin glargine, insulin glulisine, biphasic insulin aspart/insulin aspart protamine 30/70 or any of the excipients~* Patients with a (pre)proliferative retinopathy (an optic fundus examination should have been performed within the 2 years prior to study entry)~* Pregnant or lactating women~* Patients who are unable to fill in the PRO (Patient Reported Outcomes) questionnaires~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin glargine + Insulin glulisine (Type: EXPERIMENTAL): Daily injection of insulin glargine plus one injection of mealtime insulin glulisine at the main meal
- Premixed insulin (Type: ACTIVE_COMPARATOR): twice daily premixed insulin (before breakfast and evening meal).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Internet-Based Clinical Information and Blood Sample Collection From Patients With Non-Small Cell Lung Cancer Who Never Smoked Cigarettes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older~* histologically and/or cytologically proven diagnosis of non-small cell lung cancer~* never smoker, defined as having smoked less than 100 cigarettes over one's life-time~* completed survey and inclusion form~* signed informed consent~Exclusion Criteria:~* previous history of cancer (other than lung cancer, except for superficial skin cancers)~* living outside the United States~* patients who cannot read English (as materials will only be written in English)~* unable to understand the protocol or to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Never-smokers with lung cancer (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Biofreeze® vs. a Placebo on Knee Osteoarthritis Walking Gait Characteristics and Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* must have been diagnosed with bilateral knee osteoarthritis (OA) and be able to perform all study procedures~Exclusion Criteria:~* less than 40 years of age, pregnancy, cancer, rheumatoid arthritis, a total or partial knee replacement, and/or a corticosteroid injection within the past 4 weeks

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Biofreeze (Type: EXPERIMENTAL): The Biofreeze® gel will contain 3.5% menthol while the placebo will be the same formula with menthol removed and a menthol fragrance added so it is non-distinguishable from the real Biofreeze® gel. The dose of both gels will be 5 mL per knee, which is consistent with previous studies who reported a treatment effect for topical gels containing menthol (1 mL of gel for every 200 cm2 of surface area). The treatment will be applied by the investigator using a gloved hand and syringe containing 5mL of gel. The gel will be applied to the anterior and posterior knee from superior patella to the quadriceps insertion over a period of 5 seconds. The participant will wait 15 minutes, rate the pain in their knees.
- Placebo (Type: SHAM_COMPARATOR): The Biofreeze® gel will contain 3.5% menthol while the placebo will be the same formula with menthol removed and a menthol fragrance added so it is non-distinguishable from the real Biofreeze® gel. The dose of both gels will be 5 mL per knee, which is consistent with previous studies who reported a treatment effect for topical gels containing menthol (1 mL of gel for every 200 cm2 of surface area). The treatment will be applied by the investigator using a gloved hand and syringe containing 5mL of gel. The gel will be applied to the anterior and posterior knee from superior patella to the quadriceps insertion over a period of 5 seconds. The participant will wait 15 minutes, rate the pain in their knees

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of a Fibrate and a Statin on Endothelial Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than 30 years~* Adult-onset DM (defined as fasting glucose greater than 125 mg/dl or by ongoing treatment with an oral hypoglycemic agent) or metabolic syndrome (defined as at least 3 of the following: 1. HDL less than 40 mg/dl for men or less than 50 mg/dl for women; 2. triglycerides greater than 150 mg/dl; 3. waist circumference greater than 40 inches for men and greater than 35 inches for women; 4. fasting glucose greater than 100 mg/dl).~* LDL cholesterol level less than 140 mg/dl~* Able to provide informed consent and complete study procedures~Exclusion Criteria:~* Change in therapy for glucose control or blood pressure less than 1 month before entry~* Hemoglobin A1C greater than 8.0%.~* Renal insufficiency (serum creatinine greater than 1.6 mg/dl in men or 1.5 mg/dl in women.~* Any investigational drug less than 1 month before entry.~* Pregnancy (excluded by urine pregnancy test at study entry with ongoing use of reliable form of birth control) or lactation~* Liver function tests or serum creatinine kinase (CK) greater than 3 times upper limit of normal.~* Clinically evident major illnesses or other problem that would make participation inappropriate~* Clinical history of symptomatic cholelithiasis~* Patients with coronary artery disease, peripheral arterial disease, or cerebral vascular disease will not be enrolled if they are currently taking lipid-lowering therapy~* Patients taking more than 40 mg/day of atorvastatin will be excluded. There is no ceiling level for patients taking fibrates.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fenofibrate First (Type: ACTIVE_COMPARATOR): Fenofibrate 145 mg/day for 8 weeks First and Atorvastatin 20 mg/day for 8 weeks Second
- Atorvastatin First (Type: ACTIVE_COMPARATOR): Atorvastatin 20 mg/day for 8 weeks First and Fenofibrate 145 mg/day for 8 weeks Second

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Safety, Efficacy of PBI-4050 & Its Effect on Relevant Biomarkers in T2DM Patients With Metabolic Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject is 18 years of age or older.~2. Subject has signed written informed consent.~3. Subject has a clinical diagnosis of T2DM with an HbA1c level between ≥ 7.5% and ≤ 10%.~4. Subject has been receiving stable antidiabetic therapy (with or without basal insulin) for a minimum of 3 months before the screening visit.~5. Subject is able and willing to self-monitor blood glucose level at home.~6. Subject has a body mass index (BMI) of ≥ 27 kg/m2 and ≤ 45 kg/m2.~7. Subject has metabolic syndrome, having at least 3 of the 5 risk factors.~Exclusion Criteria:~1. Subject is using prandial insulin or pre-mixed insulin in addition to oral hypoglycaemic agents for blood glucose control.~2. Subject is taking basal insulin dose \> 1.0 U/kg/day.~3. Subject has recent or on-going infection requiring systemic treatment with an anti-infective agent within 30 days before screening.~4. Subject has a history of pancreatitis or diabetic ketoacidosis.~5. Subject has had at least one episode of severe hypoglycaemia in the past 12 months.~6. Subject has evidence of significant cardiovascular disease within 3 months before screening.~7. Subject has an estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m2.~8. Subject has uncontrolled hypertension.~9. Subject has a diagnosis of rheumatic or inflammatory disease; or other autoimmune or inflammatory disease.~10. Subject is concurrently taking and plans to routinely continue taking anti-inflammatory medications during the study.~11. Subject is currently using medications for the indication of (or at the doses indicated for) weight loss.~12. Subject has significantly elevated liver enzyme levels.~13. History of malignancy of any organ system, treated or untreated, within the past 5 years other than basal or squamous cell skin cancer.~14. Subject has a history of chronic alcohol or other substance abuse.~15. Subject has a history of an allergic reaction to PBI-4050 or any of its excipients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Daily dose of 6 capsules of placebo
- PBI-4050 400 mg (Type: ACTIVE_COMPARATOR): Daily dose of 2 capsules of PBI-4050 and 4 capsules of placebo
- PBI-4050 800 mg (Type: ACTIVE_COMPARATOR): Daily dose of 4 capsules of PBI-4050 and 2 capsules of placebo
- PBI-4050 1200 mg (Type: ACTIVE_COMPARATOR): Daily dose of 6 capsules of PBI-4050

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: LDE225 for Patients With PTCH1 or SMO Mutated Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has confirmed diagnosis of a select solid tumor (except medulloblastoma, basal cell carcinoma and pancreatic adenocarcinoma) or hematological malignancy (except CML, ALL and AML).~* Patient has pre-identified tumor with a PTCH1 or SMO mutation.~* Patient has received at least one prior treatment for recurrent, metastatic and /or locally advanced disease and for whom no standard therapy options are anticipated to result in a durable remission.~* Patient has progressive and measurable disease as per RECIST 1.1. or other appropriate hematological guidelines.~* Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1~Exclusion Criteria:~* Patients has received prior treatment with LDE225.~* Patients has neuromuscular disorders associated with elevated CK (i.e. inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis and spinal muscular atrophy) or are on concomitant treatment with drugs that are recognized to cause rhabdomyolysis~* Patients has primary CNS tumor or CNS tumor involvement~* Patient has received chemotherapy or anticancer therapy ≤ 4 weeks prior to starting study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDE225 (Type: EXPERIMENTAL): LDE225 800 mg (hard gelatin capsules) will be administered orally once daily on a continuous dosing schedule.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Predictive Factors for Exacerbation Outcome in Severe Refractory Asthmatics

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria :~* Male or female adults aged ≥ 18 years, who have signed an Inform Consent Form prior to initiation of any study-related procedure~* Patients with severe asthma with at least 2 exacerbations during the last 12 months that necessitated oral cortico-therapy or increase in oral cortico-therapy~Exclusion criteria :~* Pregnant or nursing women~* Patients with other chronic inflammatory lung disease~* Current smoker or a smoking history of 10 pack years or more

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of the Nanit-Insights App in Improving Infant Sleep

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infant aged 5-7 months~* Presence of a moderate to severe sleep problem at baseline~* Sleeping arrangement in which the infant sleeps in a crib at night~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 5 Months
- Maximum Age: 7 Months
- Healthy Volunteers: f

Study Arms:
- Nanit-Insights intervention group (Type: EXPERIMENTAL): Nanit-Insights is an app-based intervention that provides parents with personalized sleep recommendations, based on their infant's developmental stage and weekly sleep data.
- Nanit-monitor control group (Type: NO_INTERVENTION): Participants in the control group will be given the same monitoring device, that will serve in this group as a baby-monitor only, without providing sleep recommendations to parents.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy